EXACT Sciences Corporation (EXAS) Announces Study Results of Version 2 Stool DNA Technology
EXACT Sciences Corporation (EXAS) has announced results for the company's study regarding their Version 2 technology for colorectal cancer. This detailed study has consistent results with similar findings published earlier this year. For this reason, the final study results have been submitted for presentation at a major gastroenterology meeting scheduled to be held in 2008. Steven Itzkowitz, M.D. and Professor of Medicine at Mount Sinai School of Medicine, stated, "The results of this study compared favorably to our interim findings and further demonstrated that the Version 2 technology for detecting colorectal cancer was highly reproducible in a large set of patients."…